PRECISION BIOSCIENCES INC (DTIL)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $79k
- Feb 18 · Unusual
- Form 4 sales
- 69
- On record
- Form 144 notices
- 40
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- Nov 6, 2026Notice
Smith J. Jefferson, Chief Research Officer, filed a notice to sell 875 shares
$9k875 shares
- Nov 5, 2026Notice
Smith J. Jefferson, Chief Research Officer, filed a notice to sell 7,056 shares
$72k7,056 shares
- Feb 18, 2026Unusual
Amoroso Michael, President and CEO, sold 7.8% of their holdings
$79k20,559 shares at $3.84
- Feb 18, 2026Routine
Kelly John Alexander, Chief Financial Officer, sold 6.1% of their holdings
$31k8,149 shares at $3.84
- Feb 18, 2026Unusual
Scimeca Dario, General Counsel and Secretary, sold 8% of their holdings
$19k4,925 shares at $3.84
- Feb 18, 2026Unusual
Smith J. Jefferson, Chief Research Officer, sold 3.9% of their holdings
$19k4,925 shares at $3.84
- Feb 18, 2026Notice
Smith J. Jefferson, Chief Research Officer, filed a notice to sell 4,925 shares
$19k4,925 shares
- Feb 18, 2026Notice
Scimeca Dario, General Counsel and Secretary, filed a notice to sell 4,925 shares
$19k4,925 shares
- Feb 18, 2026Notice
Amoroso Michael, President and CEO, filed a notice to sell 20,559 shares
$79k20,559 shares
- Feb 18, 2026Notice
Kelly John Alexander, Chief Financial Officer, filed a notice to sell 8,149 shares
$31k8,149 shares
Every transaction
| Traded | Filed | Stock | Name | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | Sep 30, 2026 | DTIL | Frankel Stanley | Director | Bought | 1,000 | $6.00 | $6k | 41,478 | SEC |
| Sep 25, 2026 | Sep 29, 2026 | DTIL | Brown Melinda | Director | Bought | 1,135 | $6.27 | $7k | 45,481 | SEC |
| Sep 25, 2026 | Sep 29, 2026 | DTIL | Germano Geno J | Director | Bought | 2,609 | $6.28 | $16k | 47,492 | SEC |
| Jun 3, 2026 | Jun 5, 2026 | DTIL | Brown Melinda | Director | AwardedRestricted Stock Units | 20,979 | 20,979 | SEC | ||
| Jun 3, 2026 | Jun 5, 2026 | DTIL | Frankel Stanley | Director | AwardedRestricted Stock Units | 20,979 | 20,979 | SEC | ||
| Jun 3, 2026 | Jun 5, 2026 | DTIL | Germano Geno J | Director | AwardedRestricted Stock Units | 20,979 | 20,979 | SEC | ||
| Jun 3, 2026 | Jun 5, 2026 | DTIL | Pire Shari Lisa | Director | AwardedRestricted Stock Units | 20,979 | 20,979 | SEC | ||
| Jun 3, 2026 | Jun 5, 2026 | DTIL | Buehler Kevin | Director | AwardedRestricted Stock Units | 20,979 | 20,979 | SEC | ||
| Jun 1, 2026 | Jun 3, 2026 | DTIL | Smith J. Jefferson | Chief Research Officer | AwardedRestricted Stock Units | 57,389 | 57,389 | SEC | ||
| Jun 1, 2026 | Jun 3, 2026 | DTIL | Scimeca Dario | General Counsel and Secretary | AwardedRestricted Stock Units | 107,604 | 107,604 | SEC | ||
| Jun 1, 2026 | Jun 3, 2026 | DTIL | Kelly John Alexander | Chief Financial Officer | AwardedRestricted Stock Units | 193,688 | 193,688 | SEC | ||
| Jun 1, 2026 | Jun 3, 2026 | DTIL | Amoroso Michael | President and CEO | AwardedRestricted Stock Units | 573,888 | 573,888 | SEC | ||
| May 20, 2026 | May 22, 2026 | DTIL | Buehler Kevin | Director | Exercised or settledRestricted Stock Units | 21,000 | 0 | SEC | ||
| May 20, 2026 | May 22, 2026 | DTIL | Buehler Kevin | Director | Exercised options | 21,000 | 49,137 | SEC | ||
| May 20, 2026 | May 22, 2026 | DTIL | Frankel Stanley | Director | Exercised or settledRestricted Stock Units | 21,000 | 0 | SEC | ||
| May 20, 2026 | May 22, 2026 | DTIL | Frankel Stanley | Director | Exercised options | 21,000 | 40,478 | SEC | ||
| May 20, 2026 | May 22, 2026 | DTIL | Brown Melinda | Director | Exercised or settledRestricted Stock Units | 21,000 | 0 | SEC | ||
| May 20, 2026 | May 22, 2026 | DTIL | Brown Melinda | Director | Exercised options | 21,000 | 44,346 | SEC | ||
| May 20, 2026 | May 22, 2026 | DTIL | Pire Shari Lisa | Director | Exercised or settledRestricted Stock Units | 21,000 | 0 | SEC | ||
| May 20, 2026 | May 22, 2026 | DTIL | Pire Shari Lisa | Director | Exercised options | 21,000 | 35,028 | SEC | ||
| May 20, 2026 | May 22, 2026 | DTIL | Germano Geno J | Director | Exercised or settledRestricted Stock Units | 21,000 | 0 | SEC | ||
| May 20, 2026 | May 22, 2026 | DTIL | Germano Geno J | Director | Exercised options | 21,000 | 44,883 | SEC | ||
| Feb 18, 2026 | Feb 19, 2026 | DTIL | Amoroso Michael | President and CEO | Sold | 20,559 | $3.84 | $79k | 243,392 | SEC |
| Feb 18, 2026 | Feb 19, 2026 | DTIL | Kelly John Alexander | Chief Financial Officer | Sold | 8,149 | $3.84 | $31k | 125,883 | SEC |
| Feb 18, 2026 | Feb 19, 2026 | DTIL | Scimeca Dario | General Counsel and Secretary | Sold | 4,925 | $3.84 | $19k | 56,457 | SEC |
| Feb 18, 2026 | Feb 19, 2026 | DTIL | Smith J. Jefferson | Chief Research Officer | Sold | 4,925 | $3.84 | $19k | 121,926 | SEC |
| Feb 17, 2026 | Feb 19, 2026 | DTIL | Amoroso Michael | President and CEO | Exercised or settledRestricted Stock Units | 67,797 | 135,593 | SEC | ||
| Feb 17, 2026 | Feb 19, 2026 | DTIL | Amoroso Michael | President and CEO | Exercised options | 67,797 | 263,951 | SEC | ||
| Feb 17, 2026 | Feb 19, 2026 | DTIL | Kelly John Alexander | Chief Financial Officer | Exercised or settledRestricted Stock Units | 27,584 | 55,166 | SEC | ||
| Feb 17, 2026 | Feb 19, 2026 | DTIL | Kelly John Alexander | Chief Financial Officer | Exercised options | 27,584 | 134,032 | SEC | ||
| Feb 17, 2026 | Feb 19, 2026 | DTIL | Scimeca Dario | General Counsel and Secretary | Exercised or settledRestricted Stock Units | 16,667 | 33,333 | SEC | ||
| Feb 17, 2026 | Feb 19, 2026 | DTIL | Scimeca Dario | General Counsel and Secretary | Exercised options | 16,667 | 61,382 | SEC | ||
| Feb 17, 2026 | Feb 19, 2026 | DTIL | Smith J. Jefferson | Chief Research Officer | Exercised or settledRestricted Stock Units | 16,667 | 33,333 | SEC | ||
| Feb 17, 2026 | Feb 19, 2026 | DTIL | Smith J. Jefferson | Chief Research Officer | Exercised options | 16,667 | 126,851 | SEC | ||
| Jan 22, 2026 | Jan 22, 2026 | DTIL | Amoroso Michael | President and CEO | Sold | 34,799 | $4.17 | $145k | 196,154 | SEC |
| Jan 21, 2026 | Jan 22, 2026 | DTIL | Scimeca Dario | General Counsel and Secretary | Sold | 8,854 | $4.03 | $36k | 44,715 | SEC |
| Jan 21, 2026 | Jan 22, 2026 | DTIL | Kelly John Alexander | Chief Financial Officer | Sold | 15,213 | $4.03 | $61k | 106,448 | SEC |
| Jan 21, 2026 | Jan 22, 2026 | DTIL | Smith J. Jefferson | Chief Research Officer | Sold | 10,200 | $4.03 | $41k | 110,184 | SEC |
| Jan 21, 2026 | Jan 22, 2026 | DTIL | Smith J. Jefferson | Chief Research Officer | Exercised options | 29,166 | 120,384 | SEC | ||
| Jan 20, 2026 | Jan 22, 2026 | DTIL | Amoroso Michael | President and CEO | Exercised or settledRestricted Stock Units | 115,378 | 69,421 | SEC | ||
| Jan 20, 2026 | Jan 22, 2026 | DTIL | Amoroso Michael | President and CEO | Exercised options | 115,378 | 230,953 | SEC | ||
| Jan 20, 2026 | Jan 22, 2026 | DTIL | Scimeca Dario | General Counsel and Secretary | Exercised or settledRestricted Stock Units | 25,311 | 14,907 | SEC | ||
| Jan 20, 2026 | Jan 22, 2026 | DTIL | Scimeca Dario | General Counsel and Secretary | Exercised options | 25,311 | 53,569 | SEC | ||
| Jan 20, 2026 | Jan 22, 2026 | DTIL | Kelly John Alexander | Chief Financial Officer | Exercised or settledRestricted Stock Units | 44,363 | 26,575 | SEC | ||
| Jan 20, 2026 | Jan 22, 2026 | DTIL | Kelly John Alexander | Chief Financial Officer | Exercised options | 44,363 | 121,661 | SEC | ||
| Jan 20, 2026 | Jan 22, 2026 | DTIL | Smith J. Jefferson | Chief Research Officer | Exercised or settledRestricted Stock Units | 29,166 | 16,219 | SEC | ||
| Dec 16, 2025 | Dec 17, 2025 | DTIL | Germano Geno J | Director | Bought | 3,000 | $4.72 | $14k | 23,883 | SEC |
| Dec 16, 2025 | Dec 17, 2025 | DTIL | Frankel Stanley | Director | Bought | 2,700 | $4.70 | $13k | 19,478 | SEC |
| Dec 15, 2025 | Dec 17, 2025 | DTIL | Brown Melinda | Director | Bought | 1,381 | $4.97 | $7k | 23,346 | SEC |
| Nov 3, 2025 | Nov 4, 2025 | DTIL | Kelly John Alexander | Chief Financial Officer | Sold | 1,303 | $6.49 | $8k | 77,298 | SEC |
Sales, notices and lockups (109)
Export watchlist as CSV| Source | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Nov 6, 2026 | Smith J. Jefferson | DTIL | Chief Research Officer | Form 144 notice | 875 | $9k | Notice | SEC | |
| Nov 5, 2026 | Nov 5, 2026 | Smith J. Jefferson | DTIL | Chief Research Officer | Form 144 notice | 7,056 | $72k | Notice | SEC | |
| Feb 18, 2026 | Feb 19, 2026 | Amoroso Michael | DTIL | President and CEO | Form 4 sale | 20,559 | $79k | 7.8% | Unusual | SEC |
| Feb 18, 2026 | Feb 19, 2026 | Kelly John Alexander | DTIL | Chief Financial Officer | Form 4 sale | 8,149 | $31k | 6.1% | Routine | SEC |
| Feb 18, 2026 | Feb 19, 2026 | Scimeca Dario | DTIL | General Counsel and Secretary | Form 4 sale | 4,925 | $19k | 8.0% | Unusual | SEC |
| Feb 18, 2026 | Feb 19, 2026 | Smith J. Jefferson | DTIL | Chief Research Officer | Form 4 sale | 4,925 | $19k | 3.9% | Unusual | SEC |
| Feb 18, 2026 | Feb 18, 2026 | Smith J. Jefferson | DTIL | Chief Research Officer | Form 144 notice | 4,925 | $19k | Notice | SEC | |
| Feb 18, 2026 | Feb 18, 2026 | Scimeca Dario | DTIL | General Counsel and Secretary | Form 144 notice | 4,925 | $19k | Notice | SEC | |
| Feb 18, 2026 | Feb 18, 2026 | Amoroso Michael | DTIL | President and CEO | Form 144 notice | 20,559 | $79k | Notice | SEC | |
| Feb 18, 2026 | Feb 18, 2026 | Kelly John Alexander | DTIL | Chief Financial Officer | Form 144 notice | 8,149 | $31k | Notice | SEC | |
| Jan 22, 2026 | Jan 22, 2026 | Amoroso Michael | DTIL | President and CEO | Form 4 sale | 34,799 | $145k | 15.1% | Unusual | SEC |
| Jan 22, 2026 | Jan 22, 2026 | Amoroso Michael | DTIL | President and CEO | Form 144 notice | 34,799 | $145k | Notice | SEC | |
| Jan 21, 2026 | Jan 22, 2026 | Scimeca Dario | DTIL | General Counsel and Secretary | Form 4 sale | 8,854 | $36k | 16.5% | Unusual | SEC |
| Jan 21, 2026 | Jan 22, 2026 | Kelly John Alexander | DTIL | Chief Financial Officer | Form 4 sale | 15,213 | $61k | 12.5% | Routine | SEC |
| Jan 21, 2026 | Jan 22, 2026 | Smith J. Jefferson | DTIL | Chief Research Officer | Form 4 sale | 10,200 | $41k | 8.5% | Unusual | SEC |
| Jan 21, 2026 | Jan 21, 2026 | Scimeca Dario | DTIL | General Counsel and Secretary | Form 144 notice | 8,854 | $36k | Notice | SEC | |
| Jan 21, 2026 | Jan 21, 2026 | Smith J. Jefferson | DTIL | Chief Research Officer | Form 144 notice | 10,200 | $41k | Notice | SEC | |
| Jan 21, 2026 | Jan 21, 2026 | Kelly John Alexander | DTIL | Chief Financial Officer | Form 144 notice | 15,213 | $61k | Notice | SEC | |
| Nov 3, 2025 | Nov 4, 2025 | Kelly John Alexander | DTIL | Chief Financial Officer | Form 4 sale | 1,303 | $8k | 1.7% | Routine | SEC |
| Nov 3, 2025 | Nov 4, 2025 | Scimeca Dario | DTIL | General Counsel and Secretary | Form 4 sale | 665 | $4k | 2.3% | Routine | SEC |
| Nov 3, 2025 | Nov 4, 2025 | Amoroso Michael | DTIL | President and CEO | Form 4 sale | 3,409 | $22k | 2.9% | Routine | SEC |
| Nov 3, 2025 | Nov 3, 2025 | Kelly John Alexander | DTIL | Chief Financial Officer | Form 144 notice | 1,303 | $8k | Notice | SEC | |
| Nov 3, 2025 | Nov 3, 2025 | Amoroso Michael | DTIL | President and CEO | Form 144 notice | 3,409 | $22k | Notice | SEC | |
| Nov 3, 2025 | Nov 3, 2025 | Scimeca Dario | DTIL | General Counsel and Secretary | Form 144 notice | 665 | $4k | Notice | SEC | |
| Jul 3, 2025 | Jul 8, 2025 | Kelly John Alexander | DTIL | Chief Financial Officer | Form 4 sale | 14,827 | $63k | 16.8% | Routine | SEC |
| Jul 3, 2025 | Jul 3, 2025 | Kelly John Alexander | DTIL | Chief Financial Officer | Form 144 notice | 14,827 | $63k | Notice | SEC | |
| Mar 24, 2025 | Mar 25, 2025 | Amoroso Michael | DTIL | President and CEO | Form 4 sale | 964 | $5k | 0.9% | Routine | SEC |
| Mar 24, 2025 | Mar 24, 2025 | Amoroso Michael | DTIL | President and CEO | Form 144 notice | 964 | $5k | Notice | SEC | |
| Mar 5, 2025 | Mar 5, 2025 | List Alan | DTIL | Chief Medical Officer | Form 144 notice | 333 | $2k | Notice | SEC | |
| Mar 4, 2025 | Mar 5, 2025 | Scimeca Dario | DTIL | General Counsel and Secretary | Form 4 sale | 272 | $1k | 1.1% | Routine | SEC |
| Mar 4, 2025 | Mar 5, 2025 | Smith J. Jefferson | DTIL | Chief Research Officer | Form 4 sale | 154 | $756 | 0.2% | Routine | SEC |
| Mar 4, 2025 | Mar 4, 2025 | Smith J. Jefferson | DTIL | Chief Research Officer | Form 144 notice | 154 | $756 | Notice | SEC | |
| Mar 4, 2025 | Mar 4, 2025 | Scimeca Dario | DTIL | General Counsel and Secretary | Form 144 notice | 272 | $1k | Notice | SEC | |
| Jan 24, 2025 | Jan 24, 2025 | List Alan | DTIL | Chief Medical Officer | Form 144 notice | 672 | $3k | Notice | SEC | |
| Jan 22, 2025 | Jan 22, 2025 | Scimeca Dario | DTIL | General Counsel and Secretary | Form 4 sale | 8,928 | $43k | 26.8% | Routine | SEC |
| Jan 22, 2025 | Jan 22, 2025 | Smith J. Jefferson | DTIL | Chief Research Officer | Form 4 sale | 10,287 | $49k | 10.5% | Unusual | SEC |
| Jan 22, 2025 | Jan 22, 2025 | Scimeca Dario | DTIL | General Counsel and Secretary | Form 144 notice | 8,928 | $43k | Notice | SEC | |
| Jan 22, 2025 | Jan 22, 2025 | Smith J. Jefferson | DTIL | Chief Research Officer | Form 144 notice | 10,287 | $49k | Notice | SEC | |
| Jan 21, 2025 | Jan 22, 2025 | Amoroso Michael | DTIL | President and CEO | Form 4 sale | 36,838 | $172k | 25.6% | Routine | SEC |
| Jan 21, 2025 | Jan 21, 2025 | Amoroso Michael | DTIL | President and CEO | Form 144 notice | 36,838 | $172k | Notice | SEC | |
| Nov 4, 2024 | Nov 5, 2024 | Scimeca Dario | DTIL | General Counsel and Secretary | Form 4 sale | 588 | $5k | 6.9% | Routine | SEC |
| Nov 4, 2024 | Nov 5, 2024 | Amoroso Michael | DTIL | President and CEO | Form 4 sale | 3,012 | $25k | 9.5% | No plan | SEC |
| Nov 4, 2024 | Nov 4, 2024 | Scimeca Dario | DTIL | General Counsel and Secretary | Form 144 notice | 588 | $5k | Notice | SEC | |
| Nov 4, 2024 | Nov 4, 2024 | Amoroso Michael | DTIL | President and CEO | Form 144 notice | 3,012 | $25k | Notice | SEC | |
| Jun 10, 2024 | Jun 11, 2024 | Scimeca Dario | DTIL | General Counsel and Secretary | Form 4 sale | 93 | $1k | 1.4% | Routine | SEC |
| Jun 10, 2024 | Jun 11, 2024 | Smith J. Jefferson | DTIL | Chief Research Officer | Form 4 sale | 50 | $590 | 0.1% | No plan | SEC |
| Jun 10, 2024 | Jun 10, 2024 | Scimeca Dario | DTIL | General Counsel and Secretary | Form 144 notice | 93 | $1k | Notice | SEC | |
| Jun 10, 2024 | Jun 10, 2024 | Smith J. Jefferson | DTIL | Chief Research Officer | Form 144 notice | 50 | $589 | Notice | SEC | |
| May 2, 2024 | May 3, 2024 | Scimeca Dario | DTIL | General Counsel and Secretary | Form 4 sale | 272 | $3k | 4.6% | Routine | SEC |
| May 2, 2024 | May 3, 2024 | Smith J. Jefferson | DTIL | Chief Research Officer | Form 4 sale | 154 | $2k | 0.2% | No plan | SEC |